{
    "clinical_study": {
        "@rank": "68683", 
        "arm_group": {
            "arm_group_label": "First AZD5069, then Ketoconazole + AZD5069", 
            "arm_group_type": "Experimental", 
            "description": "AZD5069 in first period (on 1 day) and in second period (after wash out) ketoconazole alone  (on 2 days) then ketoconazole + AZD5069 (on 1 day), then again ketoconazole alone  (on 2 days)"
        }, 
        "brief_summary": {
            "textblock": "The main purpose of the study is to compare the change of the AZD5069 Pharmacokinetic\n      profile when administered with ketoconazole. Subjects will be treated first with AZD5069\n      only followed by a washout period before starting with the combined treatment (both\n      ketoconazole and AZD5069)."
        }, 
        "brief_title": "Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally.", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Asthma,", 
            "Pharmacokinetics,", 
            "Cmax,", 
            "Tmax,", 
            "\u03bbz,", 
            "AUC,", 
            "Ketoconazole,", 
            "Metabolite"
        ], 
        "detailed_description": {
            "textblock": "An open-label, fixed-sequence, single-centre phase I study to assess the effect of\n      ketoconazole on the pharmacokinetics of AZD5069 after oral administration of a single dose\n      AZD5069 to healthy male volunteers"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteers aged 18 to 50 years (inclusive).\n\n          -  Veins suitable for cannulation or repeated venipuncture.\n\n          -  Healthy volunteers with neutrophil counts within the laboratory normal reference\n             range at Screening\n\n          -  Body mass index (BMI) \u226518.0 and \u226430.0 kg/m2 calculated from height and weight at\n             screening; minimum weight 50 kg and maximum weight 100 kg.\n\n          -  Non-smokers or ex-smokers with no smoking history for the last 3 months prior to\n             screening and a smoking history of less than 10 pack years (1 pack year = tobacco\n             consumption corresponding to 20 cigarettes smoked per day for 1 year) at screening.\n\n        Exclusion Criteria:\n\n          -  Healthy volunteers with latent tuberculosis as suggested by their history and judged\n             by the Investigator\n\n          -  Healthy volunteers who belong to a high-risk group for HIV infection.\n\n          -  Known or suspected history of significant drug abuse as judged by the Investigator.\n\n          -  History of alcohol abuse or excessive intake of alcohol as judged by the\n             Investigator.\n\n          -  Plasma donation within 1 month of screening or any blood donation/blood loss >500 mL\n             during the 3 months and/or 1350 mL within the 12 months prior to screening."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01735240", 
            "org_study_id": "D3550C00011"
        }, 
        "intervention": [
            {
                "arm_group_label": "First AZD5069, then Ketoconazole + AZD5069", 
                "description": "AZD5069 15 mg (3x5 mg capsules) single administration", 
                "intervention_name": "AZD5069", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "First AZD5069, then Ketoconazole + AZD5069", 
                "description": "Ketoconazole  400 mg (2x200 mg tablets)", 
                "intervention_name": "Ketoconazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ketoconazole"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Phase I,", 
            "healthy volunteers,", 
            "fixed-sequence,", 
            "open-label,", 
            "ketoconazole,", 
            "combination,", 
            "safety"
        ], 
        "lastchanged_date": "February 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom"
                }
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Fixed-sequence, Single-centre Phase I Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of AZD5069 After Oral Administration of a Single Dose AZD5069 to Healthy Male Volunteers", 
        "overall_official": [
            {
                "affiliation": "AstraZeneca Pharmaceutical", 
                "last_name": "Bengt Larsson, Dr.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "AstraZeneca Pharmaceutical", 
                "last_name": "Gillian Pilbrow", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Quintiles Drug Research Unit at Guy's Hospital", 
                "last_name": "Leonard Siew, DR.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "(AUC(0-t)) area under the plasma concentration-time curve from time zero to time of last quantifiable concentration, (Cmax) observed maximum plasma concentration, (\u03bbz) terminal rate constant, (t\u00bd\u03bbz) terminal half-life, (tmax) time to reach maximum plasma concentration (tmax), (CL/F) apparent oral clearance (AZD5069 only), (Vz/F) apparent volume of distribution.", 
                "measure": "Pharmacokinetics of AZD5069 (15 mg) and a metabolite (AZ13587715) measured by AUC, AUC(0-t), Cmax, \u03bbz, t\u00bd\u03bbz, tmax, CL/F (AZD5069 only), Vz/F (alone and  in combination with Ketoconazole)", 
                "safety_issue": "No", 
                "time_frame": "Day 1,  Day 2 at 24 hours post dose and Day 3 at 48 hours post dose in period 1 and  Day 1, 2, 3 at 48 hours post dose and Day  4 at 72 post dose in period 2."
            }, 
            {
                "measure": "Pharmacokinetics of Ketoconazole  measured by AUC(0-t) and Cmax (in combination with AZD5069)", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 2, 3 at 48 hours post dose and Day  4 at 72 post dose in period 2."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01735240"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Numbers of circulating neutrophil in blood measured by AZD5069 administration alone and in combination with Ketoconazole", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1, 2, 3 at predose, 4, 8, 12, 24, 48 hours post dose in period 1 and Day 1, 2, 3, 4 at predose, 4, 8, 12, 24, 48 hours post dose"
            }, 
            {
                "description": "Measures: laboratory assessments (clinical chemistry, haematology, urinalysis), vital signs (blood pressure, pulse rate, including body temperature), physical examination and 12-led electrocardiogram.", 
                "measure": "Safety of AZD5069 (15 mg) in combination with Ketoconazole by assessing a panel of adverse events measures: laboratory assessments, vital signs, physical examination and 12-led electrocardiogram.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 months"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}